Decision/Regulate/
Adopted
NPPA caps trade margin on 137 non-scheduled anti-cancer medicines at 30% of MRP
India's NPPA capped trade margins on 137 non-scheduled anti-cancer medicines at 30% of MRP, which led companies to cut MRPs substantially and is expected to save patients and the system an estimated ₹3,541 crore.
Actors and targets
Targets 137 non-scheduled anti-cancer medicinesitem30% Trade Margin Cappolicy
Source
On October 17, 2026, the National Pharmaceutical Pricing Authority (NPPA) capped the trade margin on 137 non-scheduled anti-cancer medicines, including patented ones, at 30% of the maximum retail price (MRP); revised prices take effect on November 9, 2026
Not established
- Date known only to the year
- Exact year of the post update date
- Effective date of the revised MRPs
- Duration or review period of the cap
Extracted detail
- Decision maker
- National Pharmaceutical Pricing Authority (NPPA)
- Country
- India
Related decisions
Same kind only, ranked by embedding similarity to this record.